H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)

Tip Ranks
2025.11.14 23:39
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Douglas Tsao maintains a Buy rating on Coherus Biosciences with a $7.00 price target. Tsao, a 5-star analyst, has a 22.0% average return and 53.85% success rate. Maxim Group also issued a Buy rating, while TR | OpenAI reiterated a Hold rating. Tsao covers the Healthcare sector, focusing on stocks like Protagonist Therapeutics and Alkermes.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Coherus Biosciences today and set a price target of $7.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Tsao is a 5-star analyst with an average return of 22.0% and a 53.85% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes.

In addition to H.C. Wainwright, Coherus Biosciences also received a Buy from Maxim Group’s Jason McCarthy in a report issued on November 7. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Coherus Biosciences (NASDAQ: CHRS).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer